drugset / Trial / NCT06150040
Acute Myeloid Leukemia Treated With With NETrin Abs in Combination With [AZACITIDINE + VENETOCLAX]
NaSingle-groupOpen-labelTreatment
Summary
The aim of this study is to investigate the safety and the clinical activities of NP137 when combined with Azacitidine and Venetoclax in patients with refractory acute myeloid leukemia after 2 cycles of Azacitidine and Venetoclax.
Timeline
- Start
- 2024-09-11
- Primary completion
- 2025-02-18
- Completion
- 2025-02-18
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | NP137 | Monoclonal antibody | 9 mg/kg | Intravenous |
| Subject | NP137 | Monoclonal antibody | 14 mg/kg | Intravenous |
| Background | Azacitidine | Other / unclassified | 75 mg/m2 | Subcutaneous |
| Background | Venetoclax | Small molecule | 70 mg | Oral |